The Role of Polymeric Biomaterials in the Treatment of Articular Osteoarthritis.
Carmen Velasco-SalgadoGloria María Pontes-QueroLuis García-FernándezMaria Rosa AguilarKyra de WitBlanca Vázquez-LasaLuis RojoCristina AbradeloPublished in: Pharmaceutics (2022)
Osteoarthritis is a high-prevalence joint disease characterized by the degradation of cartilage, subchondral bone thickening, and synovitis. Due to the inability of cartilage to self-repair, regenerative medicine strategies have become highly relevant in the management of osteoarthritis. Despite the great advances in medical and pharmaceutical sciences, current therapies stay unfulfilled, due to the inability of cartilage to repair itself. Additionally, the multifactorial etiology of the disease, including endogenous genetic dysfunctions and exogenous factors in many cases, also limits the formation of new cartilage extracellular matrix or impairs the regular recruiting of chondroprogenitor cells. Hence, current strategies for osteoarthritis management involve not only analgesics, anti-inflammatory drugs, and/or viscosupplementation but also polymeric biomaterials that are able to drive native cells to heal and repair the damaged cartilage. This review updates the most relevant research on osteoarthritis management that employs polymeric biomaterials capable of restoring the viscoelastic properties of cartilage, reducing the symptomatology, and favoring adequate cartilage regeneration properties.
Keyphrases
- extracellular matrix
- rheumatoid arthritis
- drug delivery
- knee osteoarthritis
- induced apoptosis
- stem cells
- healthcare
- cell cycle arrest
- cancer therapy
- drug release
- bone regeneration
- anti inflammatory drugs
- gene expression
- genome wide
- tissue engineering
- dna methylation
- cell death
- body composition
- smoking cessation
- high speed